Last deal

$250M

Amount

Post-IPO Debt

Stage

06.04.2016

Date

3

all rounds

$443.35M

Total amount

date founded

Financing round

General

About Company
Anacor Pharmaceuticals develops small-molecule therapeutics to treat fungal, bacterial, and inflammatory diseases.

Industry

Sector :

Subsector :

founded date

01.01.2000

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Debt

IPO status

Private

Description

Anacor Pharmaceuticals is a biopharmaceutical company that develops topical applications of small-molecule therapeutics to treat fungal, bacterial, and inflammatory diseases. Its lead product candidate, AN2690, is a topical antifungal for toenail onychomycosis, and it is also developing AN2728, AN0128, AN2718, and AN2898 for various indications, including psoriasis, vaginal candidiasis, and skin fungal infections. Anacor has discovered and is developing five clinical compounds, including GSK 2251052, a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed to GlaxoSmithKline.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Cerimon Pharmaceuticals

Cerimon Pharmaceuticals

Cerimon Pharmaceuticals develops and sells therapeutics for autoimmune diseases and inflammation.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

South San Francisco, CA, USA

total rounds

4

total raised

$72.73M
Corbus Pharmaceuticals

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. is developing and commercializing novel therapeutics for inflammatory and fibrotic diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Norwood, MA, USA

total rounds

15

total raised

$424.65M
Omeros

Omeros

Omeros develops therapeutics for inflammation, coagulopathies, and CNS disorders.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Seattle, WA, USA

total rounds

21

total raised

$927.05M
Anthera Pharmaceuticals

Anthera Pharmaceuticals

Anthera Pharmaceuticals develops and sells treatments for inflammation-related diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

Hayward, CA, USA

total rounds

5

total raised

$101.5M
M&A Details
1

Transaction name

Acquired by

Pfizer

announced date

16.05.2016

price

$5.2B

Financials

Funding Rounds
9
3

Number of Funding Rounds

$443.35M

Money Raised

Their latest funding was raised on 06.04.2016. Their latest round Post-IPO Debt

Date 
Funding Round 
Investors 
Money Raised 
Lead 
06.04.2016
$250M
Hercules Capital

Hercules Capital

Hercules Capital, Inc. provides senior secured venture growth loans to high-growth, innovative venture capital-backed companies.

Sector

Investment Banking and Brokerage Services

Subsector

Diversified Financial Services

Keywords

Financial Services, Venture Capital, Finance

Location

Palo Alto, CA, USA

total rounds

2

total raised

$6.5M

count Of Investments

225

count Of Exists

65
U.S. Department of the Treasury

U.S. Department of the Treasury

The Department of the Treasury manages the money resources of the United States.

Sector

Investment Banking and Brokerage Services

Subsector

Diversified Financial Services

Keywords

Financial Services, Government

Location

Washington Cir NW, Washington, DC, USA

count Of Investments

35

count Of Exists

2
Co-Investors
Investors
8
4

Number of lead investors

8

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Series E, Venture - Series Unknown
No
Series E
Schering AG

Schering AG

Bayer is a global enterprise that specializes in healthcare, nutrition, and high-tech materials.

Sector

Pharmaceuticals and Biotechnology

Subsector

Pharmaceuticals

Location

Wedding, Berlin, Germany

count Of Investments

2

count Of Exists

1
Care Capital

Care Capital

Care Capital invests in entrepreneurial companies developing pharmaceutical assets.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Pharmaceuticals, Financial Services, Biotechnology

Location

Princeton, NJ, USA

count Of Investments

26

count Of Exists

11
Venrock

Venrock

Venrock partners with entrepreneurs to build disruptive, successful companies.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital, Financial Services

Location

Palo Alto, CA, USA

count Of Investments

619

count Of Exists

216
Anders Hove

Anders Hove

Anders Hove is the Partner and Founder at acorn Bioventures. Attended INSEAD.

current job

Acorn Bioventures
Acorn Bioventures

People

Founders
2
Lucy Shapiro
Lucy Shapiro

Lucy Shapiro

Lucy Shapiro, Ph.D., one of our co-founders, has served as a member of our board since our inception in 2000. She is also the co-chair of our scientific advisory board. Dr. Shapiro, the Virginia and D.K. Ludwig Professor of Cancer Research and Director of the Beckman Center in the School of Medicine at Stanford University, has been at Stanford University since 1989. Dr. Shapiro is a Fellow of the American Association for the Advancement of Sciences and has been elected to the National Academy of Sciences, the American Academy of Microbiology, the American Academy of Arts and Sciences and the Institute of Medicine of the National Academy of Sciences for her work in the fields of molecular biology and microbiology. She was elected to the American Philosophical Society and received the Selman Waksman Award from the National Academy of Sciences in 2005. She was a non-executive director of GlaxoSmithKline from 2001 to 2006 and is on the board of Gen-Probe, Incorporated. She received a B.S. from Brooklyn College and a Ph.D. in molecular biology from the Albert Einstein School of Medicine.

current job

Anacor Pharmaceutical
Anacor Pharmaceutical

organization founded

2

Lucy Shapiro

Stephen Benkovic
Stephen Benkovic

Stephen Benkovic

Stephen J. Benkovic, also known as Steve, Ph.D., was a Scientific Advisor at Ascent Biomedical Ventures and Azevan Pharmaceuticals, Inc. until January 27th 2016. Stephen Benkovic is a Scientific Partner, Rho Ventures at Rho Capital Partners, Inc. Stephen Benkovic began working with the firm in the mid-1990s prior to joining as a Scientific Partner in 2001. He also serves as a Special Limited Partner at Care Capital. Stephen Benkovic is a Co-Founder and Director at Anacor Pharmaceuticals Inc. He is a Director of Boragen Inc. His current and recent Scientific Advisory Board seats include Senomyx, Solexa, Dihedron, Archemix, and Cumbre. He serves as a Member of Scientific Advisory Board of Odyssey Thera, Inc. He is the Member of Scientific Advisory Board of Adnexus Therapeutics, Inc. Stephen Benkovic serves as a Member of Science Advisory Board at Myriant Technologies LLC. Stephen Benkovic is the Evan Pugh Professor of Chemistry and Eberly Chair of Chemistry at Penn State University. After a period as a Postdoctoral Research Associate at the University of California, Santa Barbara, he joined the Chemistry Department at Penn State University in 1965 and became a full Professor of Chemistry in 1970, followed by recognitions as an Evan Pugh Professor of Chemistry, and in 1988, the holder of the Eberly Chair in Chemistry. Stephen Benkovic's work has been recognized by awards and fellowships including: Alfred P. Sloan Fellowship, NIH Career Development Award, Guggenheim Fellowship, the Pfizer Award in Enzyme Chemistry, the Gowland Hopkin Award, the Repligen Award for Chemistry of Biological Processes, the Alfred Bader Award, the Chemical Pioneer Award from the American Institute of Chemists, and the Christian B. Afinsen Award. His research has emphasized the study of the mechanisms of enzyme-catalyzed reactions. He formerly headed the Scientific Advisory Board of GlaxoSmithKline. Stephen Benkovic recent work has focused on the mechanism of action of the folate requiring transformylase enzymes in de novo purine biosynthesis, the characteristics of enzymes in antibiotic resistance, the assembly and kinetic characteristics of the T4 replication complex; the importance of dynamic coupling of proximal and distal residues on the function of dihydrofolate reductase, and the development of novel catalysts based on biological materials. Stephen Benkovic earned a Ph.D. in Organic Chemistry from the Cornell University. He received a B.S. in Chemistry and an A.B. in English literature from the Lehigh University.

current job

Anacor Pharmaceutical
Anacor Pharmaceutical

Stephen Benkovic

Employee Profiles
41
Paul L Berns

Paul L Berns

Chief Executive Officer & President

Ryan T Sullivan

Ryan T Sullivan

Executive Vice President & General Counsel

Carmen R Rodriguez

Senior Vice President of Regulatory Affairs & Quality

Lee T. Zane

Lee T. Zane

Medical Director

James R. Marconi

James R. Marconi

Vice President of Finance & Controller

Yasheen Zhou

Head of computational chemistry group, senior research fellow

Jacob J. Plattner

Jacob J. Plattner

Senior Vice President of Research

Lucy Shapiro

Lucy Shapiro

Co-Founder & Board of Directors

Activity

Recent News
0